Helsinn Family Business Establishes $50m Start-Up Investment Fund
The family-owned Swiss firm Helsinn has taken its pastoral business approach into the incubation of promising biotech startups by setting up a $50m fund for injecting seed capital into promising prospects.
You may also be interested in...
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.
Privately-owned Swiss firm preparing for its first solo launch in the US by doubling its sales force.